Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies

• Published in: Journal of clinical pharmacology Vol. 57; no. 6; p. 720
• Main Authors: Shi, Jack G, Bowman, Kevin J, Chen, Xuejun, Maleski, Janet, Leopold, Lance, Yeleswaram, Swamy
• Format: Journal Article
• Language: English
• Published: England 01.06.2017
• Subjects: Adult; Aged; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors; Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism; Kynurenine - blood; Male; Middle Aged; Models, Biological; Neoplasms - blood; Neoplasms - metabolism; Oximes - blood; Oximes - pharmacokinetics; Oximes - pharmacology; Sulfonamides - blood; Sulfonamides - pharmacokinetics; Sulfonamides - pharmacology; Tryptophan - blood; INCB024360; PK/PD; epacadostat; indoleamine 2,3-dioxygenase; immunotherapy

Epacadostat (EPA, INCB024360) is a selective inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) and is being developed as an orally active immunotherapy to treat advanced malignancies. In the first clinical study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacody...